Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-Aza uridine 5'-monophosphate is a synthetic nucleoside monophosphate analogue and the monophosphorylated form of the antimetabolite nucleoside analogue known as 6‑azauridine. It is structurally related to uridine monophosphate but contains a nitrogen atom at position six of the pyrimidine ring (hence "aza"). This compound acts primarily as an inhibitor of orotidine‑5'‑phosphate decarboxylase (EC 4.1.1.23), interfering with de novo pyrimidine biosynthesis and thus inhibiting RNA synthesis in rapidly dividing cells. It has been studied for its antineoplastic properties and as an experimental tool in biochemical research[2][3][4][5]. There are no approved clinical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-aza uridine 5'-monophosphate.